Medpace Holdings (MEDP) experienced a significant intraday decline of 26.22% on Thursday, extending heavy losses from pre-market and post-market sessions.

The sharp sell-off was triggered by the announcement that company President Jesse Geiger has formally notified the board of his intention to resign, raising immediate concerns about management stability and strategic continuity. This negative sentiment was compounded by Deutsche Bank cutting its price target on Medpace from $480 to $425 just before the pre-market session, adding downward pressure to the stock.

Furthermore, an investor lawsuit alleging misleading book-to-bill guidance has challenged the credibility of the company's future targets, contributing to the sustained negative investor reaction that began in the post-market session and continued through pre-market trading into the regular session.